1. Home
  2. ENTA vs DCGO Comparison

ENTA vs DCGO Comparison

Compare ENTA & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • DCGO
  • Stock Information
  • Founded
  • ENTA 1995
  • DCGO 2015
  • Country
  • ENTA United States
  • DCGO United States
  • Employees
  • ENTA N/A
  • DCGO N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • DCGO Managed Health Care
  • Sector
  • ENTA Health Care
  • DCGO Health Care
  • Exchange
  • ENTA Nasdaq
  • DCGO Nasdaq
  • Market Cap
  • ENTA 164.6M
  • DCGO 144.7M
  • IPO Year
  • ENTA 2013
  • DCGO N/A
  • Fundamental
  • Price
  • ENTA $7.51
  • DCGO $1.41
  • Analyst Decision
  • ENTA Buy
  • DCGO Strong Buy
  • Analyst Count
  • ENTA 5
  • DCGO 4
  • Target Price
  • ENTA $18.40
  • DCGO $3.74
  • AVG Volume (30 Days)
  • ENTA 173.3K
  • DCGO 459.6K
  • Earning Date
  • ENTA 08-08-2025
  • DCGO 08-07-2025
  • Dividend Yield
  • ENTA N/A
  • DCGO N/A
  • EPS Growth
  • ENTA N/A
  • DCGO N/A
  • EPS
  • ENTA N/A
  • DCGO N/A
  • Revenue
  • ENTA $64,462,999.00
  • DCGO $520,500,658.00
  • Revenue This Year
  • ENTA N/A
  • DCGO N/A
  • Revenue Next Year
  • ENTA $2.75
  • DCGO $4.08
  • P/E Ratio
  • ENTA N/A
  • DCGO N/A
  • Revenue Growth
  • ENTA N/A
  • DCGO N/A
  • 52 Week Low
  • ENTA $4.09
  • DCGO $1.23
  • 52 Week High
  • ENTA $15.92
  • DCGO $5.68
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 51.19
  • DCGO 42.40
  • Support Level
  • ENTA $7.15
  • DCGO $1.35
  • Resistance Level
  • ENTA $8.31
  • DCGO $1.54
  • Average True Range (ATR)
  • ENTA 0.48
  • DCGO 0.08
  • MACD
  • ENTA 0.01
  • DCGO -0.00
  • Stochastic Oscillator
  • ENTA 55.73
  • DCGO 27.91

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

Share on Social Networks: